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SUMMARY
About a fifth of all human cancers worldwide are caused by infec-
tious agents. In 12% of cancers, seven different viruses have been
causally linked to human oncogenesis: Epstein-Barr virus, hepa-
titis B virus, human papillomavirus, human T-cell lymphotropic
virus, hepatitis C virus, Kaposi’s sarcoma herpesvirus, and Merkel
cell polyomavirus. Here, we review the many molecular mecha-
nisms of oncogenesis that have been discovered over the decades
of study of these viruses. We discuss how viruses can act at differ-
ent stages in the complex multistep process of carcinogenesis.
Early events include their involvement in mutagenic events asso-
ciated with tumor initiation such as viral integration and inser-
tional mutagenesis as well as viral promotion of DNA damage.
Also involved in tumor progression is the dysregulation of cellular
processes by viral proteins, and we describe how this has been
investigated by studies in cell culture and in experimental animals
and by molecular cellular approaches. Also important are the mo-
lecular mechanisms whereby viruses interact with the immune
system and the immune evasion strategies that have evolved.
INTRODUCTION
The history of cancer research is a history of trends, and perhapsno topic exemplifies this more than the role of viruses in the
etiology of malignancy (1). As described in more detail in History
of Tumor Virology below, it began with the discovery in 1911 of a
filterable agent that was able to transmit sarcomas in chickens (2),
and later this was shown to be a retrovirus that had transduced a
gene, v-src, derived from a cellular homolog, illustrating the con-
cept of proto-oncogenes and oncogenes (3). During the 1970s and
1980s, viral transformation of cells in culture by retroviruses such
as Rous sarcoma virus (RSV) and specifically of human cells as
shown by the small simian DNA tumor virus simian virus 40
(SV40) became widely used as models in cancer research labora-
tories. Such research received less emphasis in the 1990s, especially
with the advent of research into the tumor suppressor genes (4). In
addition, research into the role of viruses in the etiology of human
cancers also became less regarded at that time. Today, there is clear
evidence for the involvement of seven different viruses in the eti-
ology of human cancers, and this is the subject of this review.
In the context of human cancer, malignancy is defined as the
ability of cells to grow progressively and kill their host (5). For this
to happen, it is necessary for a solid tumor to acquire several hall-
mark biological capabilities during the process of multistep devel-
opment of the tumor (6). These include a sustained proliferative
capacity, the ability to induce new angiogenesis, invasion, and
metastasis. To study the molecular and cellular biology of cancer
cells, culture systems have been developed to assess growth char-
acteristics important for their malignant character, such as trans-
formation and tumorigenicity. Transformation is manifested by
the acquisition of a number of cellular properties that comprise
the transformed phenotype. These include the loss of proliferative
control, the ability to grow in a substrate-independent fashion
(growth in soft agar), failure to show contact inhibition, charac-
teristic alterations in cell morphology, and changes in cell energy
metabolism, e.g., increased glucose transport. Tumorigenicity is a
measure of the ability of cells to grow progressively and form a
tumor after inoculation, usually subcutaneously, into an immu-
nocompromised experimental animal. However, it is important
to note that transformation and tumorigenicity are experimental
models, and care should be taken when analyzing and interpreting
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them, especially when using cell lines. For example, the NIH 3T3
fibroblast cell line can begin to exhibit some of the properties of
the transformed phenotype if subcultured improperly or to a high
passage number (7, 8). Likewise, “untransformed” BALB/3T3
cells are able to form solid tumors if they are inoculated attached
to glass beads (9, 10). Nevertheless, transformation in cell culture
has been used extensively as a tool to study molecular and cellular
mechanisms in the field of cancer research and is often cited as
evidence for a role for a particular virus or viral gene in the etiology
of cancer. In this review, we consider the evidence for the involve-
ment of viruses in human cancer and the molecular mechanisms
involved. It is of note that the many pathways affected by oncovi-
ruses to establish tumors are relevant as “hallmarks of cancer” (6).
HISTORY OF TUMOR VIROLOGY
The notion that viruses have a role in the etiology of malignancy
originated from the studies published in 1911 by Peyton Rous,
who reported a filterable agent (Rous sarcoma virus [RSV]) in cell
extracts of a chicken tumor that could transmit the tumor into
healthy chickens (2). The discovery of this retrovirus opened up
the field of tumor virology, demonstrating that some cancers
could have an infectious etiology and eventually leading to the
discovery of oncogenes (11). In the 1930s, two tumor viruses were
described in mammals, suggesting the possibility that viruses may
play a similar causal role in human cancers (12). Shope papillo-
mavirus was isolated from keratinous carcinomas from the cot-
tontail rabbit (13), and mouse mammary tumor virus (MMTV) is
a cancerous agent, or “milk factor,” that is transmitted by mothers
to young mice in their milk (14). In the 1950s, mouse leukemia
virus (15) and mouse polyomavirus (16) were discovered.
In humans, the first tumor viruses were discovered in the 1960s
and 1970s (17, 18). Epstein-Barr virus (EBV) (also called human
herpesvirus 4 [HHV-4]) was first observed in cells cultured from
Burkitt’s lymphoma by electron microscopy, marking the starting
point of human tumor virology (19). In the next several years, it
was recognized that EBV is a herpesvirus and that EBV infections
are ubiquitous, with more than 90% of people becoming infected
by their twenties (20). Immunofluorescence assays showed high-
level immune responses to EBV antigens in patients with Burkitt’s
lymphoma or nasopharyngeal carcinoma (21), and biopsy speci-
mens of these cancers showed the presence of EBV DNA (22). EBV
has a 168- to 184-kbp linear double-stranded DNA genome and
contains 85 genes, terminal repeat regions, and an internal repeat
region (17, 23). During latency, the genome circularizes to form
an episome that is maintained at constant copy number and was
the first episome discovered in eukaryotes (with the exception of
certain plants) (24). EBV is lymphotropic but can also infect epi-
thelial cells, which are the primary site of replication initially (25,
26). There are two subtypes of this virus, EBV-1 and EBV-2, which
differ at the EBNA locus (17).
Hepatitis B was recognized as a serum-borne infectious jaun-
dice in the 1940s, and hepatitis B virus (HBV) was identified in the
1970s (27). HBV, which causes acute and chronic liver infections,
liver failure, cirrhosis, and hepatocellular carcinoma (HCC), is a
hepadnavirus with a small, circular, partially double-stranded
DNA genome (28). Epidemiological studies of HBV infection and
HCC in the 1970s associated HBV with the development of HCC,
and clear-cut epidemiological evidence of an etiological role was
published in 1981 (29). HBV transmission is via blood or other
body fluids, such as by close contact, heterosexual sex, contact
with blood as occurs in health care settings, perinatal transmission
(a major means in Asia), household contact via saliva, etc. About
half of all people who are infected with HBV remain asymptom-
atic. Perinatal infection is important for HBV but not for HCV
(30). The symptoms of hepatitis B appear after an incubation pe-
riod of about 3 to 4 months, with most patients recovering but
1% developing fulminant hepatitis B, which can lead to can lead
to acute liver failure requiring liver transplantation. About 5%
develop chronic infections, which can cause chronic active hepa-
titis and cirrhosis (17). Hepatitis B has its highest prevalence is in
sub-Saharan Africa and East Asia, where infection is more com-
monly acquired during childhood and results in 5 to 10% of the
adult population being chronically infected, compared to 0.5% in
the United States. Infection at the time of birth commonly leads to
chronic infection: 80 to 90% of infants who are infected in the first
year of life go on to develop chronic infections (common in Asia),
and 30 to 50% of children who are infected before the age of 6
years develop chronic infections (common in Africa).
Human papillomaviruses (HPVs) are an established etiological
agent of human cancer. A role for HPV in the etiology of cervical
carcinoma was first proposed by zur Hausen in the 1970s (31–33).
HPV16 and HPV18 were directly detected in cervical carcinoma
in the 1980s (34, 35). Epidemiological studies in the 1990s impli-
cated “high-risk” HPV infections in a causal role in cervical carci-
noma (17). On a global scale, HPV infections account for more
than half of all infection-linked cancers in females, whereas this is
barely 5% in males. The HPV genome is a linear double-stranded
DNA of 7 to 8 kbp (36) with up to 10 open reading frames (ORFs)
and a long control region (LCR) that regulates epithelial cell-spe-
cific transcription and is regulated by viral and cellular transcrip-
tion factors. HPV transmission occurs by mucosal contact and by
skin-to-skin contact and is facilitated by microabrasions in the
skin or mucosal epidermal surfaces. Anogenital HPV infections
usually occur by sexual contact. HPV is the major cause of cervical
carcinoma and is also involved in cancers of the anogenital tract,
penis, vulva, vagina, anus, oropharynx, and others (17). Most
HPV infections in young women are transient, but persistent in-
fection with “high-risk” genotypes may lead to the progression of
precancerous lesions and eventually invasive cancer (37). Impor-
tantly, this led to the development of the “anticancer” vaccines
Cervarix and Gardasil, which protect against infection with
HPV16 and HPV18, which are the cause of most cases of cervical
cancer. These act in a similar fashion to the HBV vaccine produced
earlier in the sense that they prevent infection and thus cancer.
In the 1970s, a peculiar clustering of leukemia cases in south-
west Japan (endemic adult T-cell leukemia/lymphoma [ATL]) led
to the isolation of a retrovirus from cell lines derived from patients
with human adult T-cell leukemia (38), and the sequence of this
virus (39) showed it to be identical to human T-cell leukemia virus
type 1 (HTLV-1), isolated from a T-cell line, which was discovered
earlier by Robert Gallo’s group and was the first known human
retrovirus (40). HTLV-1 is most prevalent in southern Japan but is
also present elsewhere, e.g., Australia and northern Canada, with
an estimated 15 to 20 million people being infected worldwide
(41). The virus is transmitted sexually and also parenterally, e.g.,
by blood transfusions, dirty needles, breastfeeding, etc., and it
accounts for 0.03% of all cancer. Latency between infection and
ATL onset is decades, and only a small percentage of infections
result in ATL (42). While HTLV-1 is found elsewhere in the world,
the family clustering of ATL in Japan has a genetic basis, perhaps
White et al.
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involving HLA type (43). The genome of HTLV-1 has a charac-
teristic retroviral organization, i.e., gag, pol, and env, but also a
region at the end designated pX, which contains genes that are
important for oncogenesis and is discussed below.
In the 1970s, it was recognized that there was a type of hepatitis
that was different from hepatitis A and hepatitis B that was spread
by transfusions (44). In 1989, Choo and coworkers isolated a
cDNA clone from a library made from the plasma of a chimpanzee
experimentally infected with non-A non-B hepatitis that encoded
an antigen associated with non-A non-B infections and was de-
rived from an 104 nucleotide positive-strand RNA (45). Infec-
tion is often asymptomatic but can lead to liver damage and cir-
rhosis. Infection is widespread, with 130 to 200 million people
infected worldwide (46), and is the foremost reason for liver trans-
plants in the United States and the Western world (47). Eighty-five
percent of HCV-infected adults go on to develop chronic infec-
tion, which leads to cirrhosis and HCC and is in stark contrast to
the case for HBV. HCV is a flavivirus with a 9,600-nucleotide
linear uncapped single-stranded RNA genome with a positive
polarity and has an uninterrupted ORF encoding a polyprotein
which is processed into 10 structural and nonstructural proteins
by host cellular and viral proteases (48). Today, HCV is spread
mainly by intravenous drug use and sexually; e.g., prison inmates
have high rates of positivity (49). The basis of oncogenesis for both
HBV and HCV is chronic inflammatory responses.
Finally, technical advances in molecular biology have allowed
the discovery of two new human oncoviruses in more recent years.
In 1994, Chang et al. (50) used a technique known as representa-
tional difference analysis, which is a PCR-based method that al-
lows the identification and characterization of unique DNA se-
quences in a diseased tissue compared to nondiseased tissue
obtained from the same patient, to isolate a unique sequence pres-
ent in Kaposi’s sarcoma. They discovered Kaposi’s sarcoma-asso-
ciated herpesvirus (KSHV), a member of the gammaherpesvi-
ruses, which is a subfamily of Herpesviridae that is distinguished
by a more variable rate of reproduction than in the other subfam-
ilies of Herpesviridae and also includes EBV (50). Kaposi’s sar-
coma is a rare skin tumor that was first described by Moritz Kaposi
in 1872 and rose to prominence in the early 1980s as an AIDS-
defining disease caused by KSHV, which is also known as human
herpesvirus 8 (HHV-8). KSHV is also the causative agent of pri-
mary effusion lymphoma (51) and multicentric Castleman’s dis-
ease (52, 53). The genome of KSHV has a 140.5-kbp coding region
with at least 81 ORFs (54). KSHV infects B lymphocytes, endothe-
lial cells, macrophages, and keratinocytes, and the receptor for
viral entry is 31 integrin (55). After infection, KSHV can circu-
larize and exist in a latent form as an episome expressing viral
latency-associated nuclear antigen (LANA), which subsequently
can be reactivated and lytically replicate to yield linear DNA mol-
ecules for the next round of infection.
The most recent human oncogenic virus to be discovered is
Merkel cell polyomavirus (MCV) (56), the only proven oncogenic
virus of the many human polyomaviruses (57). The role of animal
polyomaviruses in tumorigenesis has long been known, and two
human polyomaviruses, JC virus (JCV) and BK virus (BKV), were
identified in 1971 (58–60). More recently, at least eight new hu-
man polyomaviruses have been discovered (57), and one of these,
MCV, was identified in patients with Merkel cell carcinoma
(MCC), which is a rare but highly aggressive malignancy. MCC is
a neuroectodermal tumor that is may arise from the mechanore-
ceptor Merkel cells of the skin (61). Immunosuppression is a pre-
disposing factor for MCC (62), which raised the possibility that,
like Kaposi’s sarcoma, MCC may have an infectious origin. A
search for viral sequences that might be present in MCC was con-
ducted by Feng et al. (56) using digital transcriptome subtraction,
which is a bioinformatics method for detecting novel pathogens
by high-throughput sequencing and computational analysis. This
led to the discovery of a novel transcript with a sequence that had
homology to T antigen (T-Ag) of polyomaviruses. This was des-
ignated Merkel cell polyomavirus (MCV), a novel circular DNA
virus with a genome size of 5.4 kb, which was found to be clonally
integrated into the cell genome in 80% of cases of MCC (56).
Since the integration of viral DNA into the cell genome occurs at a
single site, this indicates that the integration event preceded the
expansion of the tumor, providing important evidence for the role
of MCV in neoplasia. Similarly, a metastatic tumor from the same
patient had a pattern of integration identical to that of the primary
tumor (56). Subsequent studies of other MCC patients have con-
firmed that integration of MCV occurs in a large percentage of
cases, providing molecular evidence for a causative role of MCV in
oncogenesis (63–66). Importantly, the integration event reveals a
signature for large-T-antigen disruption in a specific region that
prematurely truncates the protein (67). The molecular signifi-
cance of this is discussed below. Seroepidemiological studies indi-
cate that infection by MCV is widespread in the human popula-
tion (68–70). The site of replication of MCV may be the Merkel
cells of the skin, since it is associated with MCC (61). Studies of
MCV replication have proved to be difficult because the virus
cannot be cultivated in tissue culture beyond the stage of primary
low-level virion production from cells transfected/infected with
viral genome (71).
Thus, there are seven currently known human cancer viruses.
Below we discuss the status of our understanding of the molecular
mechanisms whereby these viruses induce tumors.
THE ISSUE OF ESTABLISHING CAUSALITY
The establishment of a generally held view that a particular virus
causes cancer has often been a long, drawn-out process, since the
barriers to acceptance are very high and rightly so. The criteria that
are usually used to assign causality are the consistency of associa-
tion at the epidemiological and/or molecular level and the tumor-
igenicity of the agent in animal models or its transforming ability
in cell culture (72). The classic standard for causality in medical
research is the application of Koch’s postulates (73). Briefly, these
are as follows: (i) the microorganism must be found in all cases of
the disease but not in healthy individuals unless there can be
asymptomatic carriers, (ii) the microorganism must be isolated
from the disease and propagated in culture, (iii) the microorgan-
isms from cultures should cause disease when reintroduced, and
(iv) the microorganism must be reisolated from the inoculated
host with the disease and be identical to the original agent. These
postulates are very difficult to apply to human viruses and cancer
for a number of reasons, which have been described in a number
of recent reviews (17, 74) and will be summarized briefly here.
First, it is often the case that there is a long latency period
between primary viral infection and occurrence of the cancer. For
example, the latency period between HTLV-1 infection and onset
of acute T-cell leukemia is on the order of decades, and only a
minor fraction of individuals who are infected will go on develop
ATL (42). Similarly, virus infection can often be subclinical, and
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so it is difficult to establish the time of infection. For many cancer
viruses, infection is widespread but the associated cancer is rare.
For example, seroepidemiological studies show that 63 to 75% of
the population has been exposed to MCV (70), but the incidence
of Merkel cell carcinoma (MCC) is 0.17/100,000 to 0.34/100,000
in the United States (75). Some cancers often require cofactors as
well as the virus to develop. For example, in the case of HPV,
cofactors in the development of cervical cancer include smoking,
hormonal contraceptives, nutrition, and coinfections with other
organisms, such as herpesvirus, Chlamydia, and HIV (17). In
some cancers, the virus may integrate irreversibly into the host
genome during pathogenesis (e.g., with MCV [56]), so it is impos-
sible to culture infectious progeny. The outcome of virus infection
may vary depending on host factors such as immune status; e.g.,
the impaired immune system in HIV/AIDS is a major predispos-
ing factor for Kaposi’s sarcoma. Viruses may employ different
mechanisms in the multistage process of carcinogenesis: HPV
promotes chromosomal instability and so may directly contribute
to cellular genetic changes (76), whereas the role of HBV and HCV
in HCC development is more indirect, involving chronic inflam-
matory responses and taking many decades while mutations ac-
cumulate, often aided by exposure to aflatoxin and alcohol. Fi-
nally, for many viruses there is a lack of an animal model, and
indeed some, e.g., MCV, lack even a cell culture system. It should
also be noted that viruses can cause cancers with histopathological
features similar to those of cancers caused by other factors.
In order to address these problems, a number of approaches
have been suggested, such as criteria defining environmental
causes, consistency, specificity, temporality, plausibility, etc. (77),
and epidemiological approaches (78). Guidelines have been pro-
posed for relating a given virus to a human cancer (17). Briefly,
these are as follows: (i) the geographical distribution of viral in-
fection should match that of cancer after adjustment for other
cofactors. (ii) viral markers (e.g., antiviral antibody titer or pres-
ence of virus-specific cytotoxic T cells) should be higher in cases of
cancer than in controls, (iii) viral markers being present should
precede the tumor and have an incidence that matches the inci-
dence of the tumor, (iv) prevention of viral infection (e.g., by
vaccination) should decrease incidence of the tumor, (v) the virus
should exhibit transforming properties with human cells in cul-
ture, and (vi) the virus should induce tumors in animals and this
should be preventable by viral neutralization. Recently, human-
ized mouse models have been developed to study viral infections,
e.g., for HBV and HCV (79) and EBV (80). In practice, these issues
can be complex and depend on the virus. For example, there is an
increased risk of certain types of noninfectious cancers in HIV-1-
infected individuals, presumably due to the defective cell-medi-
ated immunity (81), but HIV-1 is not considered an oncovirus.
Clearly, much research into the epidemiology, virology, and mo-
lecular biology of a virus is needed before it can be accepted as an
oncovirus.
VIRAL MECHANISMS OF TRANSFORMATION AND
TUMORIGENICITY
Early studies on the regulation of cell proliferation and discoveries
in the field of signal transduction employed the transformation of
cultured cells by oncoviruses as model systems. Transformation of
human cells by SV40 was first reported in the early 1960s (82). The
key cellular tumor suppressor and cell cycle regulator p53 was
identified as a cellular protein that bound to large T antigen in an
SV40-transformed mouse cell line (83). Another tumor suppres-
sor and cell cycle regulator, pRb, is the protein product of the
retinoblastoma susceptibility gene Rb and was found to be iden-
tical to p105, a cellular protein that binds to the E1A transforming
proteins of adenovirus, a virus that can immortalize primary cells
in vitro but is not thought to be associated with human cancer
(84). Similarly studies of tyrosine phosphorylation of proteins in
Rous sarcoma virus-transformed chicken embryo fibroblasts led
to the discovery of pp42 (85), which was later identified as p42/
mitogen-activated protein kinase (MAPK) (86), a central signal
transduction protein. Investigation of the molecular mechanisms
used by the viral transforming proteins, including those of the
seven human oncoviruses, is still an active area of research today,
(Table 1).
In general, cancer development is a complex multistep process,
and this is also true for cancers arising from the effects of viruses,
which exert effects on different stages of tumor formation de-
pending on the virus. Viruses can exert their effects on the early
stage of oncogenesis involving genetic events that are involved in
tumor initiation or, alternatively, act at later stages by modulating
signaling pathways involved in the regulation of cell proliferation,
apoptosis, replicative immortality, and others, such as tumor pro-
motion.
Several human oncoviruses, including HPV, can cause genetic
changes to the host genome that can initiate and contribute to
carcinogenesis. In the case of HPV, the viral genome is normally
episomal in basal epithelial cells that have become infected by
virus but are not producing virus. However, in HPV-transformed
cells, i.e., those that are infected and have begun malignant pro-
gression, it often becomes integrated into the host DNA by ran-
dom integration events which leave the E6 and E7 oncogenes (see
below) intact and still expressed, underlining their importance in
tumorigenesis (87). Integration is not a normal part of the life
cycle of HPV, and when it occurs, HPV becomes unable to com-
plete its life cycle. Indeed, there is evidence that both episomal and
integrated HPV can be present at the same time during the early
phase of tumorigenesis and that episomal HPV become less com-
mon at later stages, but there is continued and robust expression
of E6 and E7. E6 and E7 are thought to have a role in carcinogen-
esis for the high-risk HPVs (HPV16, -18, and -31) (17). Cells with
integrated HPV proliferate more rapidly and form a pool of im-
mortalized cells where it is possible for further mutations to occur
and lead to carcinoma formation. Enhancing this, E6 and E7 cause
genetic instability (87), and it has been reported that acquirement
of elevated levels of chromosomal instability is associated with the
integration of HPV16 in cervical keratinocyte cell lines (88).
An approach that is much used in the study of viral oncopro-
teins is to express them in cell culture and analyze cellular prop-
erties that are altered, e.g., proliferation, ability to grow in soft
agar, loss of contact inhibition, cell morphology, and metabolic
changes (i.e., the transformed phenotype). Caveats in the inter-
pretation of such experiments are important, as was stressed in the
introduction; nevertheless, they may be indicative of the role of a
protein in viral carcinogenesis. For HPV16, E6 is a 158-amino-
acid protein that is present in both the nucleus and the cytoplasm
and will immortalize human cells at low efficiency but will coop-
erate with E7 to transform primary human keratinocytes (89). E6
alone will transform NIH 3T3 cells, and it cooperates with Ras to
transform primary rodent cells (90).
Another approach to the study of human viral oncoproteins is
White et al.
466 cmr.asm.org Clinical Microbiology Reviews
to use animal model systems. Immunocompromised mice, such
as nude mice, can be injected with virus, as either virions or virus-
infected cells, or alternatively, transgenic mice that express a viral
oncogene in a tissue-specific fashion can be produced. When HPV
E6 and E7 from high-risk papillomavirus type 16 were expressed
in the skin of transgenic mice, the development of preneoplastic
lesions was potentiated, and a higher percentage of these mice
went on to develop into locally invasive carcinomas (91). E6 and
E7 were expressed at high levels in these tumors compared to the
preneoplastic lesions, and the site of expression was the prolifer-
ating, poorly differentiated epidermal cells. Thus, the HPV16 E6
and E7 genes contribute to epidermal carcinogenesis in an animal
model. Further analysis has shown evidence that E6 and E7 con-
tribute in different ways to carcinogenesis in transgenic mice, with
E7 promoting benign tumor formation, E6 accelerating progres-
sion of these tumors to malignancy, and E6 and E7 together co-
operating in tumor induction (92). In cell culture, E7 has immor-
talizing potential with NIH 3T3 cells and, in combination with
human telomerase reverse transcriptase (hTERT), human pri-
mary keratinocytes (93).
The oncogenic properties of the high-risk HPVs (HPV16, -18,
and -31) are thought to involve mainly the proteins E6 and E7
(89), (94–97). As shown in Fig. 1, cellular p53 is a target of E6, and
E6 binds and degrades p53 through an E3 ubiquitin protein ligase
called cellular E6-associated protein (E6-AP), which results in the
ubiquitination and degradation of p53 (98). E6 also binds p300/
CBP, which is a p53 coactivator, resulting in indirect interference
with p53, binds and inactivates p21 and p27, hDlg, MUPP1, and
hScrib, and may also affect Notch signaling and activate the
hTERT promoter via an E6/Myc/Max complex, bind proapop-
totic Bak, and promote phosphorylation of pRb. A detailed review
of E6 interactions has been published (99).
The other important protein in HPV carcinogenesis is E7, a
phosphoprotein with two zinc fingers that shows some structural
and functional similarity to adenovirus E1A and SV40 large T
antigen. E7 can self-assemble into spherical oligomers and is phos-
phorylated by casein kinase II, and this is inhibited by myeloid-
related protein 8 (MRP-8) and MRP-14, which are growth inhib-
itory and complex with pRb, p107, and p130, resulting in
phosphorylation and E2F release, which promotes cell cycle pro-
gression (100). As shown in Fig. 2, E7 can also bind histone
deacetylases (HDACs), the S4 subunit of proteasome, Mi2,
AP-1, MPP2, TATA-binding protein (TBP), and hTid-1 (17), and,
like E6, it induces chromosomal instability and cooperates with E6
in this induction (89). Thus, the high-risk HPVs are powerful
human cancer viruses that express oncoproteins that act at multi-
ple stages in tumorigenesis from events involved in tumor initia-
tion to later stages of tumor promotion.
EBV and KSHV are DNA viruses but persist during latency as
episomes without integration into host DNA. Episomal EBV,
however, expresses EBNAs and LMP-1, which may be functional
depending on the type of latency involved and whether its onco-
genic role is direct or indirect. EBV infects B cells and epithelial
cells, resulting in either lytic replication in epithelial cells or entry
into a latent state in B cells, where the EBV genome becomes
circularized and is present in the nucleus as an episome present in
chromatin. Latent episomal virus is maintained at a constant copy
number by cellular DNA polymerase and expresses only a portion
of the proteins that it encodes (up to 8 of 100). These proteins
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most importantly EBV nuclear antigen 1 (EBNA-1) (101), which
is a sequence-specific DNA-binding phosphoprotein that is in-
volved in EBV episomal maintenance, DNA replication, and pos-
sibly transformation (102). EBNA-1 binds to host DNA and may
regulate transcription of cellular genes. Chromatin immunopre-
cipitation (ChIP) and sequence analysis have identified and de-
fined cellular sites to which EBNA-1 binds (103), although these
are not as strong or specific as the binding to viral ori-P. As shown
in Fig. 3, EBNA-2 is a nuclear protein and a transcriptional coacti-
vator that induces expression of a number of cellular genes, e.g.,
EBV receptor/CR2 (CD21) and CD23 antigen (FcεRII), and also
transactivates expression of the c-Src family nonreceptor tyrosine
kinase member c-Fgr, (feline Gardner-Rasheed sarcoma viral on-
cogene homolog) (104). EBNA-2 requires a cellular factor to bind
its cis-responsive DNA element, and this has been identified as
RBPJ kappa (105). EBNA-2 can also activate Notch signaling
(106) and considerably increases PU.1-dependent upregulation of
ubiquitin carboxyl-terminal esterase L1 (UCHL1), which is a mul-
tifunctional ubiquitin thiolesterase that is implicated in the pro-
gression of some lymphoid cancers, including EBV-associated
lymphomas (107). Expression of the other latency-associated EBV
genes, LMP-1 and LMP-2, is also regulated by EBNA-2 (108).
LMP-1 has the ability to induce invasiveness and metastasis
factors, e.g., matrix metalloproteinase 9, which disrupts the base-
ment membrane (109). Also, LMP-1 is a viral mimic of a member
of the tumor necrosis factor receptor (TNFR) superfamily of pro-
teins that is constitutively active, does not require ligand, and ac-
tivates the NF-B, MAPK, phosphatidylinositol 3-kinase (PI3K)/
Akt, and JAK/STAT signal transduction pathways, while LMP-2A
engages a number of potential signaling pathways such as MAPK,
PI3-K/Akt, NK-B, and STAT (110, 111).
EBNA-2 has a critical role in lymphocyte immortalization, and
EBNA-1, EBNA-2, LMP-1, EBV-encoded small RNAs 1 and 2
(EBER1 and EBER2), and the BamHI rightward transcripts
(BARTs) act together via multiple molecular mechanisms to effect
cellular transformation by EBV in Burkitt’s lymphoma and naso-
pharyngeal carcinoma. Several cellular approaches have been in-
conclusive about the potential of EBNA-1 to act as an oncogene,
FIG 1 Schematic representation of signaling by high-risk human papillomavirus HPV E6. Targets for HPV E6 (99) (center column) and biological effects (right
column) are shown. E6AP, E6AP ubiquitin-protein ligase (UBE3A); IRF-3, interferon-regulatory transcription factor 3; E6BP, E6 binding protein; E6TP,
E6-targeted protein 1; AP-1, activator protein 1; hDig/hScrib, human homolog of Drosophila disc-large tumor suppressor/human homolog of Drosophila
Scribble; p300, p300 transcriptional coactivating protein; MAML1, human homolog of Drosophila mastermind; TERT, telomerase reverse transcriptase.
FIG 2 Schematic representation of signaling by high-risk human papillomavirus HPV E7. Targets for HPV E7 (center column) and biological effects (right
column) are shown. CUL2, Cullin 2; E2F1, adenovirus E2 promoter binding factor 1; KIP-1, cyclin-dependent kinase (CDK) inhibitor 1B; CIP1, CDK-
interacting protein 1; HDACs, histone deacetylases; ISGF-3, interferon-stimulated gene factor 3; IGFBP-3, insulin-like growth factor-binding protein 3.
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but in cultures of Burkitt’s lymphoma cell lines, increases in ex-
pression of the Nox2 catalytic subunit of the NADPH oxidase,
levels of reactive oxygen species (ROS), and genomic instability
have been reported upon constitutive or conditional expression of
EBNA-1. Similarly, in CNE2 cells, expression of EBNA-1 in-
creased Nox2 expression and levels of ROS, which paralleled in-
creased telomere instability. Thus, it has been suggested that
EBNA-1 may act as an oncoprotein by contributing to oxidative
stress and genomic instability (103). EBNA-2 is a nuclear protein
that has a critical role in lymphocyte immortalization. Thus, the
P3HRI variant of EBV has a deletion encompassing EBNA-2, is
nonimmortalizing, and fails to induce these types of changes in
cellular gene expression (112). Another EBV protein, LMP-1, is a
principal oncoprotein and has transforming properties in Rat-1
fibroblasts as assayed by loss of contact inhibition (113). EBERs,
which are the most abundant EBV transcripts in latently infected
cells but are untranslated, confer the ability to grow in soft agar,
form tumors in nude mice, resist alpha interferon (IFN-)-in-
duced apoptosis, and induce the autocrine expression of interleu-
kin-10 (IL-10), which acts as an autocrine growth factor (114,
115). EBV BARTs and EBV-encoded microRNAs are also poten-
tially significant with respect to cellular transformation (116).
Similarly, KSHV gene products show oncogenic properties, as dis-
cussed below (117). There are conflicting reports on the ability of
B-cell-directed expression of EBV EBNA-1 to induce B-cell lym-
phoma in transgenic mice, with reports of tumor induction (118)
and cooperativity with Myc in lymphomagenesis (119). In an-
other study, lymphoma was not observed, but the EBNA-1 mice
exhibited pulmonary adenomas (120). This may be due to the
different genetic backgrounds of the mice used in these studies.
Expression of the Epstein-Barr virus LMP-1 has also been re-
ported to induce B-cell lymphoma in transgenic mice (121). As
noted above, expression of the EBV EBER1 and EBER2 transcripts
confers clonability in soft agarose and tumorigenicity in immuno-
deficient mice.
Like EBV, KSHV is a DNA virus of the gammaherpesvirus
family and has a large DNA genome. Remarkably, KHSV has an
extraordinary array of proteins that mediate transformation.
KHSV has appropriated a number of genes that mimic human
cytokines and cytokine response signaling pathway proteins, e.g.,
vIL-6, vMIP-I, vFLIP, vBCL-2, v-cyclin-D, vGPCR, and vIRF-1,
indicating a novel strategy of molecular mimicry to overcome
tumor suppressor pathways and drive neoplasia (122). Latent ep-
isomal KSHV expresses a protein known as latency-associated nu-
clear antigen (LANA), a 222- to 232-kDa nuclear protein which
tethers the viral episomal DNA to the cellular chromosomes via
histone H1 binding. LANA is the main KSHV latent protein ex-
pressed in all types of KSHV-associated malignancies and is a key
player in viral oncogenesis (123). LANA is a transcriptional regu-
lator which suppresses KSHV replication and transcriptional ac-
tivator (Rta) expression, thus inhibiting viral lytic replication and
maintaining latency (123). As shown in Fig. 4, LANA is highly
multifunctional in its transforming actions, interacts with many
other cellular proteins, and is involved in the disruption of a num-
ber of cellular proliferation control mechanisms: it binds to gly-
cogen synthase kinase 3 (GSK-3), which is a signaling protein
in the Wnt pathway and negatively regulates -catenin, and
thereby increase levels of -catenin and the activity of the down-
stream transcription factor TCF/LEF (124). Other targets include
p53, which is bound and inactivated by LANA (125), and hypo-
FIG 3 Schematic representation of signaling by EBV EBNA-2. Targets for EBV EBNA-2 (center column) and biological effects (right column) are shown. c-fgr,
feline Gardner-Rasheed sarcoma viral oncogene homolog; UCHL1, ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase); MAPK, mitogen-activated
protein kinase; PI3K, phosphatidylinositol 3-kinase; JAK/STAT, Janus kinase/signal transducer and activator of transcription.
FIG 4 Schematic representation of signaling by KSHV LANA. Targets for
KSHV LANA (latency-associated nuclear antigen) (center column) and bio-
logical effects (right column) are shown. GSK-3, glycogen synthase kinase 3;
pRb, retinoblastoma protein; Brd2, bromodomain containing 2.
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phosphorylated (active) pRb, which results in the transactivation
of E2F-responsive promoters (117). Additional targets have also
been reported, including AP-1, which is activated and thus in-
duces IL-6 expression, Id-1, Sp1 to induce the telomerase pro-
moter, RING3/Brd2, myeloid cell nuclear differentiation antigen
(MNDA), p300, and p300 (123).
While LANA is the chief player in KSHV latency and oncogen-
esis, other proteins have roles, including the following: v-cyclin D
(ORF72), which is always expressed in Kaposi’s sarcoma and pri-
mary effusion lymphoma, complexes with Cdk9, and causes phos-
phorylation of histone H1 and pRb, promoting the G1-to-S tran-
sition; vGPCR (ORF74), which activates phosphoinositide
signaling, transforms NIH 3T3 fibroblasts, and upregulates cyto-
kine production by activating NF-B, AP-1, and NFATs via Rac1/
Pak1; and vFLIP (vFLICE-inhibitory protein, ORF71), which
binds to FLICE (Fas-associated death domain protein and caspase
8) and acts as a dominant negative inhibitor of Fas-receptor-me-
diated apoptosis. Other KSHV proteins involved in transforma-
tion include latency-associated membrane protein (LAMP) (K1,
ORF75), which has sequence similarity to EBV LMP-1 and acti-
vates Ras/MAPK and NF-B, and viral interferon-regulatory fac-
tor 3 (vIRF-3), which inhibits the transactivation of p53, protein
kinase R (PKR)-activated apoptosis, and caspase 3 activation (17,
126). Thus, KSHV has evolved a complex and sophisticated mo-
lecular strategy to effect latency and manipulate cellular signal
transduction processes, and these disruptions are involved in on-
cogenesis. Primary rat cells transformed by expression of KSHV
LANA in combination with Ha-Ras are them tumorigenic in nude
mice (117). KSHV kaposin (K12)-transformed Rat-3 fibroblasts
are also tumorigenic in nude mice (127).
Unlike EBV and KSHV, for HBV, the DNA genome is small
and encodes only a few proteins. HBx exerts multiple pleiotropic
effects, but its functions remain not well understood. HBx and
hepatitis B surface antigen (HBsAg) are important in transforma-
tion. Integration of the HBV genome into the host genome can
occur, but this takes place at no unique site in the cell genome but
rather can occur in many different places, and this can be an im-
portant mechanism in the development of HCC in HBV-infected
individuals, where integration causes disruption of key genes that
regulate proliferative signaling. Recurrent preferential integration
sites include CCNE1 (cyclin E1, which regulates the G1/S transi-
tion), FN1 (fibronectin), MLL4 (a histone methyltransferase),
ROCK1 (a kinase that regulates actin polymerization), SENP5 (a
protease for sumoylated proteins), and TERT (telomerase), which
regulates cell senescence, as was reviewed recently by Xu et al. and
Guerrieri et al. (128, 129). Other mechanisms for tumorigenesis
have also been described for HBV, which has a small genome
(3,200 bp) and encodes only four proteins: core antigen
(HBcAg), which is a 183- to 185-amino-acid protein that can be
phosphorylated and which also has an extracellular variant
(HBeAg); DNA polymerase, which is 90 kDa and also has reverse
transcriptase activity; HBsAg, which is the surface antigen; and
HBx (the functions of these proteins are discussed below). How-
ever, it should be noted that HBV carcinogenesis is generally
thought to be indirect, it takes around 50 years for gene mutations
to accumulate (with inflammatory responses also being impor-
tant), and it is rare that a direct effect of insertional mutagenesis is
seen. Unlike HBV, HCV is an RNA virus, and there is no possibil-
ity for it to integrate its genetic material into the host genome
(130).
The HBV HBx protein is oncogenic in experimental hepato-
cellular carcinogenesis, since it is able to transform rodent hepa-
tocytes in vitro. HBx sequences persist in clonally expanding ro-
dent hepatocytes, and HBx transforms NIH 3T3 cells in
cooperation with Ras (131). Expression of the HBV protein HBx
in transgenic mice makes them susceptible to chemical carcino-
gens, and high levels of HBx expression can lead to HCC (132).
HBx acts as an oncogene in experimental HCC and accelerates
HCC development in the presence of Myc in transgenic mice
without cirrhosis and also augments their susceptibility to develop
HCC after exposure to diethylnitrosamine (a strong carcinogen).
Further, lowering the levels of HBx mRNA and protein by RNA
interference results in a reduction in the tumorigenicity of HCC
cells that constitutively express HBx (131). For HCV, in transgenic
mice expressing HCV core protein, hepatic steatosis develops
early in life and can go on to give liver adenomas and HCC (133).
The 5= half of the cDNA for HCV nonstructural protein 3 (NS3)
can transform cells in culture and confer tumorigenicity in nude
mice for NIH 3T3 cells (134), rat fibroblasts (135), and the
QSG7701 human liver cell line (136). HBsAg expression in trans-
genic mice has also been reported to lead to HCC (137). HCV core
protein transforms NIH 3T3 cells via STAT3 activation (138). The
function of HBx is not yet well understood, but it may play a part
in promoting viral transcription. HBx antigen is present mainly in
the cytoplasm but also in the nucleus and, as shown in Fig. 5,
activates the extracellular signal-regulated kinase (ERKs), stress-
activated protein kinases (SAPKs), and p38 protein kinase path-
ways (139). It has also been reported to bind to p53 (140).
HCV has a 9,600-nucleotide RNA genome encoding 10 pro-
teins. The mechanisms of HCV carcinogenesis are imperfectly un-
derstood, but core protein and NS3 are thought to be important.
HCV core protein is able to interact with numerous transcription
factors, either directly or indirectly, including hnRNPK, LZIP,
RNA helicase CAP-Rf, p53, p21, DDX3 protein, NF-B, and 14-
3-3 protein, as shown in Fig. 6. HCV core protein may be involved
in activation of the Ras/Raf/MAPK pathway, since 14-3-3 protein
associates with components of the Raf-1 kinase cascade. Consti-
tutive expression of HCV core protein leads to elevated basal ac-
tivity of MAPK kinase, as indicated by levels of phosphorylation of
ERK-1 and ERK-2. HCV core protein also suppresses the activity
of the promoter for the cyclin-dependent inhibitor p21, which is
involved in cell cycle control and tumorigenesis. The Wnt/-
catenin pathway is also involved in HCC carcinogenesis, and tran-
FIG 5 Schematic representation of signaling by HBV HBx. Targets for HBV
HBx (center column) and biological effects (right column) are shown. ERKs,
extracellular signal-regulated kinases; SAPK, stress-activated protein kinase;
DDB1, damage-specific DNA-binding protein 1; Pin1, peptidylprolyl cis/trans
isomerase; VDAC3, voltage-dependent anion channel 3.
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scriptional upregulation of Wnt-1 and its target WISP-2 by core
protein suggests that a mechanism involving Wnt signaling may
promote cell growth. Regulation of these pathways has been re-
viewed recently (141). Another HCV protein, NS3, has been re-
ported to bind to p53 (142).
HTLV-1 is an RNA virus and belongs to the retrovirus family,
with a genome size of 8.51 kb. HTLV-1 is the causative agent of
ATL and can also cause HTLV-1-associated myelopathy/tropical
spastic paraparesis (HAM/TSP), which is a rare disease that is
thought to result from immunological aspects of host-virus inter-
actions (143). The oncogenic functions of HTLV-1 reside in the
pX region of the genome, which encodes the proteins Tax, Rex,
and others. Both Tax and Rex, which is an RNA-binding protein
involved in splicing and transport of viral mRNA, are required for
viral replication, but Tax also stimulates cell proliferation and is
thought to be the major transforming protein of HTLV-1 (144).
Transgenic mice expressing the HTLV-1 Tax protein under the
control of the HTLV-1 long terminal repeat (LTR) developed soft
tissue tumors at multiple sites, showing that Tax efficiently in-
duces mesenchymal tumors in this animal model (145). Well-
characterized posttranslational modifications of Tax are acetyla-
tion, phosphorylation, ubiquitination, and sumoylation (144).
Tax does not bind directly to DNA but instead binds and modu-
lates the activity of transcription factors; e.g., it binds to CREB at
the HTLV-1 LTR to stimulate viral transcription (146), as shown
in Fig. 7. The CREB/Tax complex is able to recruit the transcrip-
tional coactivators/acetyltransferase p300, and histone acetylation
and consequent chromatin remodeling are crucial for the tran-
scriptional transactivation functions of Tax. Also of importance is
the activation of NF-B, which occurs via both canonical and
noncanonical pathways and is essential for Tax-mediated trans-
formation and leukemogenesis (144). A plethora of other activi-
ties that are involved in transformation are mediated by Tax, and
these are still not fully elucidated but include acceleration of the G1
phase of the cell cycle, activation of cyclin E and Cdk2, binding
and stabilization of cyclins D3 and D2 and cyclin D/Cdk4 com-
FIG 6 Schematic representation of signaling by HCV core protein. Targets of HCV core protein (center column) and biological effects (right column) are shown.
CAP-Rf, RNA helicase; DDX3, DEAD3;1, upregulation.
FIG 7 Schematic representation of signaling by HTLV-1 Tax. Targets for HTLV-1 Tax (center column) and biological effects (right column) are shown.1,
upregulation;2, downregulation; SRF, serum response factor; NF-B, nuclear factor B; CREB, cyclic AMP (cAMP) response element-binding protein; Cdk4,
cyclin-dependent kinase 4; Cdk6, cyclin-dependent kinase 6; Chk1, checkpoint kinase 1; Chk2, checkpoint kinase 2; DNA pol , DNA polymerase ; DNA-PK,
DNA-dependent protein kinase; ATR, ataxia telangiectasia and Rad3 related; ATM, ataxia telangiectasia mutated; Fox04, forkhead transcription factor FoxO4;
MDM2, mouse double minute 2 homolog.
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plexes, promotion of pRb phosphorylation and consequent E2F
release, binding of hypophosphorylated pRb and thereby promot-
ing its degradation, activation of telomerase hTERT expression,
and inhibition of cellular DNA repair at several levels (144). Tax
also causes changes in the intracellular redox status, which pro-
mote DNA damage that may also be important in initiating the
genetic changes in HTLV-1-infected T cells that eventually pro-
mote neoplasia (147). It is thus clear that Tax is a prime example of
how a viral accessory protein can be highly multifunctional.
HTLV-1 can integrate into the DNA of the host in ATL, and the
clonal nature of these integration sites indicates that the integra-
tion preceded expansion of the leukemic cells and is thus evidence
for insertional mutagenesis by HTLV-1 (148).
In addition to Tax, there are other accomplices in pathogenesis
that are expressed from the pX region, namely, p12, p8, p30, and
p13 (149). Expression of Tax may be sufficient for the immortal-
ization of human T lymphocytes in vitro. In one study, herpesvirus
saimiri recombinant viruses expressing Tax were found to be able
to immortalize cultured primary human CD4 cord blood lym-
phocytes. However, in another study with primary human T cells,
Tax was found to have weak oncogenic activity. Although Tax
expression was necessary for growth of the primary T cells, addi-
tion of IL-2 was also required to drive the T cells into cell cycle
progression (147). These findings suggest that Tax activity alone is
not enough to cause immortalization and that other HTLV-1 pro-
teins are involved in transformation and leukemogenesis. In this
regard, p30II has been found to promote cell survival against
genotoxic insults in HTLV-1-infected lymphocytes, and so it is
possible that, in addition to Tax, the additional activities of other
HTLV-1 proteins, such as p12, p8, p30, and p13, are important for
transformation (149). p12 has the ability to activate this the JAK/
STAT pathway, which signals the effect of the cytokine IL-2 T-
lymphocyte proliferation. Thus, expression of p12 results in an
increase in STAT5 phosphorylation, DNA binding, and transcrip-
tional activation, which decreases the IL-2 requirement for cell
proliferation (150). Microarray analyses indicate that expression
of p30 can modulate the levels of proteins involved in apoptosis
and the cell cycle, but the biological significance of this is not
established (149). However, it has also been reported that p30
promotes the transforming ability of c-Myc (151). The protein p8
appears to function in viral infectivity, while p13 appears to be
proapoptotic in some circumstances and its functions in viral per-
sistence are not understood (149).
MCV was first identified as a polyomavirus found to be clon-
ally integrated into the genome of most cases of MCC (56), and it
is the most recently discovered human oncovirus. As is the case
with the other human polyomaviruses (57), MCV is very common
and yet MCC is very rare, which is presumably because integration
is not part of the MCV life cycle and is an unlikely event. There is
strong evidence that this integration event is involved in the initi-
ation of the tumor, since MCV DNA was found to be clonally
integrated into a single site, indicating that the integration event
preceded tumor expansion. Moreover, a metastasis from the same
patient had an integration pattern identical to that of the primary
tumor (56). Integration of MCV has been confirmed in a large
percentage of other MCC cases by subsequent studies, providing
powerful evidence for a causative role of MCV in integration in
MCC oncogenesis (63–66). Also of note, integration always oc-
curs in such a way as to disrupt the MCV large T antigen at a
specific region, prematurely truncating the protein in a way that
prevents its function in viral DNA replication but retaining its
transforming activity (67). The mechanism of polyomaviral trans-
formation, i.e., large T- and small t-antigen function, has been
studied for many decades, starting with the discovery of SV40 in
1960, so this has provided a strong basis for studying MCV trans-
formation. Coimmunoprecipitation experiments showed that
MCV large T antigen was bound to pRb in all the Merkel’s carci-
noma samples examined by Shuda et al. (67). In the case of trans-
formation by polyomaviruses such as SV40, JCV, and BKV, many
oncogenic protein-protein interactions between large T antigen
and cellular proteins, including p53, pRb, IRS-1, -catenin, and
others, and between small t antigen and protein phosphatase 2A
(PP2A) have been described, as we have previously reviewed (58–
60). In the case of MCV, some of these interactions are conserved,
as in the case of pRb binding to large T antigen (152, 153) and its
involvement in transformation. On the other hand, an intact p53-
binding site in MCV large T antigen is not required, suggesting
that transformation by MCV is p53 independent (67). However,
MCV proteins can have novel interactions with cellular proteins
(Fig. 8) that have not been reported for SV40 or JCV, such as that
between large T antigen and the lysosomal sorting protein binding
to Vam6p (154). Other examples are binding of MCV small t
antigen to the translation initiation factor 4E-binding protein 1
(4E-BP1), causing hyperphosphorylation, which results in dys-
regulated cap-dependent translation (155), and to E3 ubiquitin
ligase Fbw7 (156) (Fig. 8). Investigating the mechanisms of MCV
FIG 8 Schematic representation of signaling by MCV large T antigen (T-Ag) and small t antigen (t-Ag). Targets for MCV T-Ag and t-Ag (center column) and
biological effects (right column) are shown.1, upregulation;2, downregulation. pRb, retinoblastoma protein; Vam6p, vacuolar protein-sorting gene product;
TLR9, Toll-like receptor 9; 4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1; FBW7, F-box/WD repeat-containing protein 7; NEMO, NF-B
essential modulator.
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transformation is a new and active area of research that is still
revealing novel aspects of MCV T- and t-antigen transformation.
ROLE OF THE IMMUNE SYSTEM: IMMUNITY AND VIRAL
MECHANISMS OF IMMUNE EVASION
The human body has elaborated a complex variety of immune
defense mechanisms that prevent viral infections and eliminate
virally infected cells. In turn, viruses have adapted by evolving
different strategies for evading immune responses. In general, it
can be said that these mechanisms are also involved in the im-
mune evasion of virally induced cancers and that this is not be-
cause the virus evolved to cause cancer but rather is a secondary
result of the mechanisms that the virus deployed to evade the
elimination of virally infected cells. Indeed, this is similar to the
uncontrolled growth of virally induced tumors, which is a second-
ary result of the mechanisms that the virus evolved to enhance cell
proliferation in order to enhance viral replication or perpetuate
persistence of the viral genome. The interplay between virus and
immune system is apparent from the observation that virally in-
duced cancers, e.g., Kaposi’s sarcoma, Merkel cell carcinoma, and
EBV-associated lymphomas, are more frequent in individuals
with an impaired immune status. In this section, we examine
mechanisms involved in interactions between human cancer vi-
ruses and the immune system (Table 2).
Downregulation of the Major Histocompatibility Complex
or Associated Functions
A major mechanism mediating antiviral action by the immune
system is major histocompatibility complex (MHC) presentation
of viral epitopes to cytotoxic CD8 T cells. Cells normally present
cytosolic peptides products from protein turnover on MHC class
I molecules at the cell surface. During viral infection, proteins
degraded in the proteasome to cytosolic peptides are brought into
the endoplasmic reticulum by TAP (transporter associated with
antigen processing), where they bind to nascent MHC class I mol-
ecules, followed by display on the cell surface. Consequently,
many human oncoviruses have evolved mechanisms to subvert
this process. EBV enters a state of latency in B lymphocytes fol-
lowing primary infection, characterized by EBNA-1 expression,
which is involved in maintenance of the viral DNA episome. The
ability of latently EBV-infected cells to evade the immune system
is conferred by the glycine-alanine repeat domain of EBNA-1,
which inhibits MHC class I-restricted presentation of EBNA-1
epitopes linked in cis (157). When EBV enters the replicative phase
of infection, over 80 EBV genes become expressed, which induce
strong immune responses from CD4 and CD8 T cells, but virus
successfully replicates. Many studies have provided evidence that
this is due to the activities of several viral proteins interfering with
the different stages of the MHC class I and class II antigen presen-
tation. These include the following: inhibition of the TAP by
BNLF2a, which prevents peptide loading by MHC class I; blockage
of MHC class I molecule synthesis by BGLF5; a reduction in the
levels of mRNAs for TAP1 and the immunoproteasome subunit
bli/LMP2 by vIL-10; inhibition of MHC class I presentation at the
cell by BILF1; and inhibition of MHC class II molecules antigen
presentation by gp42/gH/gL, BGLF5, and vIL-10 (157–159). By
these mechanisms, the EBV lytic proteins effectively interfere with
CD8 and CD4 immune responses, allowing viral replication.
Downregulation of MHC expression is also a mechanism em-
ployed by HBV. In a study of MHC class I molecules on hepato-
plastoma cell lines, the expression of MHC class I molecules HLA-
ABC, HLA-E, and MICA was found to be downregulated by HBV
(160). Perturbation of antigen processing and presentation is also
a key strategy of HPV. Mechanisms of disruption of antigen pro-
cessing and presentation mediated by HPV include decreased ex-
pression of the LMP2 and LMP7 proteasome subunits, decreased
expression of the TAP1 and TAP2 peptide transporter subunits,
and decreased expression of MHC-I itself (161). The E7 protein of
high-risk HPV represses the MHC class I heavy-chain gene pro-
moter and also the bidirectional promoter that regulates expres-
sion of both LMP2 and TAP1 (162). HPV E5 downregulates MHC
TABLE 2 Human cancer viruses: mechanisms of immune evasion
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class I cell surface expression (163). The functional effect of MHC
downregulation on the cell surface of HPV-infected cells is a re-
duced recognition by T cells, leading to an escape from immuno-
surveillance. Similarly, HTLV-1 interferes with host immune re-
sponse through the action of p12, which downregulates cell
surface MHC-I expression by specifically binding to newly synthe-
sized MHC-I as well as reducing expression of ICAM-1 and
ICAM-2 (149).
Interfering with Interferon Action
Interferons (IFNs) are cytokines produced and secreted by host
cells in response to foreign pathogens such as viruses, and they
function to communicate between cells to trigger protective im-
mune defenses. IFNs were named because of their ability to inter-
fere with the process of replication of various viruses within the
host cell. Viral infection causes release of IFN, and neighboring
cells respond to it by producing protein kinase R (PKR), which
phosphorylates and inactivates eIF-2 and reduces protein synthe-
sis within the cell. Also induced following PKR activation is RNase
L, which destroys RNA to further reduce synthesis of both viral
and host proteins. Induction of type I IFN production is regulated
mainly at the transcriptional level by transcription factors called
the interferon-regulatory factors (IRFs), which are controlled by
signaling pathways involving the Toll-like receptors (TLRs).
Many oncoviruses have adapted mechanisms to escape the effects
of interferon. For example, the EBV protein LMP-1 binds Tyk2, a
signaling protein in the IFN- signaling pathway, and prevents
Tyk2 phosphorylation, which inhibits IFN--stimulated nuclear
translocation of STAT2 and thus transcriptional activation of in-
terferon-stimulated response elements (164). IRF-7, discovered in
1977 binding to the EBV Q promoter (165), is considered the
“master regulator” of type I interferons. IRF-7 is both induced and
activated by LMP-1 (166).
HTLV-1 p30 inhibits TLR4 signaling in macrophages (149).
HBV elicits a response from the host innate immune system which
is type I interferon dependent, and the virus has evolved a number
of mechanisms to suppress these, including inhibition of IFN-
and IFN- production and inhibition of type I interferon signal
transduction pathways (167). To evade the innate immune re-
sponse, the E6 and E7 proteins of high-risk HPV subtypes such as
HPV16 inhibit TLR9 transcription, resulting in functional loss of
TLR9-regulated pathways (168), as does EBV LMP-1 (169) and
MCV large T antigen (170). E6 protein can inhibit IRF-3 transac-
tivation, preventing IFN- induction (171). HCV activates signal-
ing by the Toll-like receptors to activate the signal transduction
pathways involving NF-B and IRF-3, which activates transcrip-
tion from the IFN- promoter and also induces IFN-. The ex-
pression of IFN--induced genes interferes with HCV translation
and replication (172). HCV employs a number of strategies to
evade interferon action. HCV NS3/4A protease counteracts IRF-3
activation by blocking signaling by the RIG-1 RNA helicase and
cleaving the TLR3 adaptor protein TRIF, while HCV NS5A antag-
onizes IFN- function by inducing IL-8, which interferes with
interferon action, and HCV HS5A and E2 inhibit PKR (173).
KSHV expresses proteins that subvert the intracellular path-
ways of type I interferon-mediated antiviral immunity by antago-
nizing them with effects that are wielded at various stages of the
viral life cycle, including KSHV RIF, which binds to several critical
components of the type I IFN signaling pathway such as the IF-
NAR1/IFNAR2 subunits of the type I IFN receptor, Tyk2/Jak1,
and STAT2, inhibiting phosphorylation of both Tyk2 and Jak1
(174).
Molecular Mimicry
The concept of molecular mimicry, in this context, is that a virus
can elaborate proteins that can evade host immune responses by
mimicking aspects of host immune function. KSHV is a herpesvi-
rus that is well adapted to evade the immune system using molec-
ular mimicry (122). KSHV establishes long-term latency follow-
ing infection of cells where gene expression is highly restricted,
and it can then undergo lytic replication. KSHV encodes a large
number of immunomodulatory proteins that evade the host im-
mune system, and these are deployed at distinct stages of its viral
life cycle (175). Two viral transmembrane proteins, MIR1 and
MIR2, prevent expression of MHC class I at the cell surface, and
MIR2 also downregulates ICAM-1 and B7.2 (176, 177). Expres-
sion of v-FLICE inhibits induction of apoptosis by the extrinsic
pathway by inhibiting death signaling (178). Cell-mediated cyto-
toxicity is also inhibited by the virus-encoded chemokines,
v-CCL-1, v-CCL-2, and v-CCL-3, which are secreted by KSHV-
infected cells, and viral complement control protein, which inac-
tivates complement (175). HBV elicits coordinated immune re-
sponses of both the innate and adaptive types, and the virus has
evolved a complex array of mechanisms to evade them, including
induction of immunotolerance, mutations, molecular mimicry,
and others. For example, the pre-S(21-47) sequence of HBV en-
velope protein is involved in binding of the virus to cell receptors
and has homology to the IgA heavy-chain constant region and
immunological cross-reactivity, suggesting that attachment of
HBV to cells might involve secretory components representing a
polymeric IgA receptor (179).
Generation of Escape Mutants
Viruses that have an RNA genome or have an RNA replicative
intermediate and employ a low-fidelity polymerase may generate
mutants that are antigenically different and thereby evade the im-
mune system. HBV replicates through reverse transcription of an
RNA intermediate, and hence the rate of appearance of mutant
viruses is high. Selection pressure to evade host immune clearance
readily selects out escape mutants (180). The primary events me-
diating clearance of HBV from the liver and contributing to liver
damage are effected by cytotoxic T cells, with 90% of acutely in-
fected adults resolving all clinical symptoms (181). Mutations in
viral genes may cause nonresponsiveness to viral antigens, and
these have been reported in the precore/core gene, polymerase
sequence, and pre-S/S region (182).
In the case of the RNA virus HTLV-1, in spite of the error-prone
nature of reverse transcription, HTLV-1 isolates are remarkably
similar in sequence, unlike other retroviruses, e.g., HIV-1. While
in HTLV-1 infection, about a third of peripheral blood mononu-
clear cells and half of CD4 cells are proliferating provirus-con-
taining cells, in ATL, the tumor cells are mainly CD4, CD25
mature T cells and virions, and viral mRNA or proteins are diffi-
cult to detect, but strong antiviral antibody and cellular immune
responses are readily detectable, especially against Tax (17). Even
with the host antiviral immune response, HTLV-1 is able to persist
by deploying other strategies as described above. In contrast, HCV
is an RNA virus, and the intrinsic infidelity of the HCV RNA
polymerase generates many quasispecies, helping immune eva-
sion (172).
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Other Strategies
A variety of other strategies have been employed by human onco-
viruses to avoid immune responses. One simple one is to just
express proteins at a very low level: HTLV-1 downregulates the
levels of viral gene expression but still persists through the prolif-
eration of infected cells harboring the latent viral episome (17).
HPV has evolved multiple strategies of immune evasion so as to
persist in squamous epithelia for enough time to complete the
viral replicative life cycle. This persistent HPV infection is the
principal risk factor for developing HPV-associated precancerous
lesions and cancers. Clearance of HPV-induced lesions involves
cellular immune responses, and the interplay of these responses
with viral immune evasion mechanisms determines whether HPV
infection is cleared or persists (161). The virus is able to maintain
a low profile, since it exclusively infects epithelial cells and its
replicative cycle occurs outside the basement membrane away
from immune effector cells. Also, viral proteins are not secreted
but are expressed mainly at low levels in the nuclei of infected cells
early in infection by the viral gene repressor protein E2 and usage
of rare codons, which limits viral protein translation. During the
later stages of infection, viral protein expression occurs only in the
keratinocytes of the upper layers of the epithelium, where access
by the immune system is limited, and indeed HPV infection does
not involve viremia, cell death, or cell lysis upon viral shedding. In
this way, HPV avoids activation of antigen-presenting cells, pro-
duction of cytokines, and initiation of the immune response
(161). Current models of papillomavirus latency propose that
HPV resides in the basal epithelial stem cell pool and episodically
reactivates upon stem cell division. Immunosurveillant memory T
cells resident in the tissue are thought to control the extent and
duration of these reactivation episodes (183, 184).
Finally, not much is known about the interactions of the most
recently discovered human oncovirus, MCV. It is important to
note that MCV is different from the other six human oncoviruses
in that carcinogenesis is an endpoint that lies beyond the viral life
cycle, and so viral replication is not occurring and mechanisms of
maintaining viral persistence in the face of the immune system are
not in play. As noted above, immunosuppression is an important
predisposing factor in the development of Merkel cell carcinoma
(62). Iyer et al. (185) found T-cell responsiveness to MCV T anti-
gen in tumor-infiltrating lymphocytes from MCC tumor tissues,
showing that MCC tumors are able to develop despite the pres-
ence of T cells specific for this oncoprotein (185). Recently, MCV
large T antigen was found the inhibit TLR9 expression (170).
CONCLUSIONS AND FUTURE DIRECTIONS
Over many years of cancer research, the role of viruses in onco-
genesis has been much debated. We now have a consensus that
seven different viruses are likely to have a causal role in human
cancer (Table 1). Much progress has been made over the last 30
years, and now the evidence is convincing that oncoviruses ac-
count for about 20% of human cancers worldwide (17). Research
on these viruses and the molecular mechanisms involved in the
pathologies they produce is still ongoing, and indeed these areas of
research have gone hand in hand with the advancement of basic
cancer research for decades. It remains to be seen if there will be
more viruses that will be implicated in the etiology of human
cancers. In this regard, there are two possibilities.
First, it is possible that hitherto-unknown viruses will be iden-
tified as cancer agents. Technical advancements in molecular bi-
ology continue apace, and they may reveal new agents that might
not be apparent with the use of classical virological approaches.
For example, KSHV was discovered by representational difference
analysis, which is a method that compares PCR products from
diseased tissue to those from nondiseased tissue obtained from the
same patient, thus allowing the identification and characterization
of unique DNA sequences that are specific to the disease (50).
Similarly, the most recent human oncovirus to be discovered,
MCV, was found through high-throughput sequence analysis of
RNA transcripts from Merkel cell carcinoma and then computa-
tional removal of host sequences known from high-quality refer-
ence genome data (digital transcriptome subtraction). By this
method, a novel transcript with a sequence that had homology to
the then-known polyomaviruses was identified, leading to the dis-
covery of MCV (56). Thus, it is perhaps likely that unknown vi-
ruses exist that are associated with human cancers and may be
identified in the future. In this regard, the number of members of
the family of human polyomaviruses has expanded rapidly in re-
cent years, and the roles of most of these in human diseases remain
unknown (57).
Second, there are viruses that are reported to be associated with
human cancer but for which there have not been sufficient con-
sistent data to establish a consensus in the field on their etiological
role in cancer. Examples include the polyomaviruses JCV and
BKV. JCV has long been the established agent of the central ner-
vous system (CNS) demyelinating disease progressive multifocal
encephalopathy, which is caused by lytic replication of the virus in
glial cells. JCV causes tumors in experimental animals, and there
have been reports of the presence of JCV DNA and proteins in
brain tumors and other human cancers but also reports to the
contrary (58–60), and this is further complicated by reports of
JCV DNA in normal brain tissue (186). Infection by the virus also
is very common, making epidemiological studies difficult, and
there are other issues, which were raised in The Issue of Establish-
ing Causality above. It is possible that further research into JCV
will further clarify its role in human cancer.
Another virus that has gained attention for a possible role in
cancer is the betaherpesvirus human cytomegalovirus (HCMV),
which has been suggested to be involved in a variety of brain tu-
mors (187), including gliomas (188) and medulloblastomas
(189), based on treatment data for animal models and patients
(187, 188, 189). Moreover, there are many reports that HCMV can
dysregulate signaling pathways involved in cell transformation
and malignancy (187), including tumor suppressors (p53, Rb, and
cyclins) and mitogenic signaling (PI3K/Akt, Erk, Wnt, and NF-
B), as well as the inflammatory response, immune evasion, an-
giogenesis, and invasion (190). However, as with JCV, infection in
the human population is very common, and the ubiquitous nature
of infection and the frequent persistence of HCMV in normal as
well as cancer tissue make it very difficult to evaluate its role in
human cancer (17).
Finally and most importantly, the expression of virus-specific
antigens by human tumors offers a huge opportunity to develop
preventive and therapeutic options. Already vaccines for HBV and
HPV are available and widely used. Of note, the vaccines Cervarix
and Gardasil have been developed against HPV, and both vaccines
have proven to be almost 100% effective in preventing disease
caused by the high-risk HPV types, HPV16 and -18, which to-
gether account for 70% of all cervical cancers, as well as other
anogenital cancers. The development of novel therapeutics that
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exploit virus-specific proteins, such as immunotherapy, targeted
monoclonal antibodies, and small-molecule inhibitors, is an im-
portant future goal.
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